دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions — proceedings from the CEC Summit 2018
AbhinavSharmaMD, PhDabKenneth W.MahaffeyMDcCharles MichaelGibsonMDdKaren A.HicksMDe†Karen P.AlexanderMDfMariaAliMBBS, MBAgBernard R.ChaitmanMDhClaesHeldMDPhDiMarkHlatkyMDjWIlliam SchuylerJonesMDfRoxanaMehranMDkVenuMenonMDlFrank W.RockholdPhDfJonathanSeltzerMD, MBA, MAmErnestSpitzerMDnoMatthewWilsonRNfRenato D.LopesMD, PhDf
doi : 10.1016/j.ahj.2021.12.012
Volume 246, April 2022, Pages 93-104
Clinical events adjudication is pivotal for generating consistent and comparable evidence in clinical trials. The methodology of event adjudication is evolving, but research is needed to develop best practices and spur innovation.
Rationale and design of a randomized trial evaluating an external support device for saphenous vein coronary grafts
EmiliaBagiellaPhDaJohn D.PuskasMDbAlan J.MoskowitzMDaAnnetine C.GelijnsPhDaJohn H.AlexanderMDcJagatNarulaPhDdPeter K.SmithMDcKelleyHutchesonMDeHelena L.ChangMSaJames S.GammieMDfAlexanderIribarneMDgMary E.MarksBSNaYuliyaVengrenyukPhDhKeisukeYasumuraMDhSamanthaRaymondMPHaBradley S.TaylorMDiOritYardenPhDjEyalOrionMDj…Daniel J.GoldsteinMDu
doi : 10.1016/j.ahj.2021.12.009
Volume 246, April 2022, Pages 12-20
Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design
HironoriHaraMDabPatrick W.SerruysMD, PhDbcNeilO'LearyPhDdChaoGaoMDbefAliciaMurrayPhDdElaineBreslinPhDdScotGargMD, PhDgChristopheBureauPhDhJohan HCReiberPhDiEmanueleBarbatoMD, PhDjAdelAminianMDkLucJanssensMDlLiesbethRosseelMDmEdouardBenitMDnGianlucaCampoMDoVincenzoGuiducciMDpGianniCasellaMDqAndreaSantarelliMDr…YoshinobuOnumaMD, PhDb
doi : 10.1016/j.ahj.2021.12.018
Volume 246, April 2022, Pages 32-43
Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial
Connie N.HessMD, MHSabWarren H.CapellMDabMichael R.BristowMD, PhDbcWolframRufMDdeMichaelSzarekPhDabfDavid A.MorrowMD, MPHgJose C.NicolauMD, PhDhChristopher A.GraybillPhDcDebraMarshallMDcJudithHsiaMDabMarc P.BonacaMD, MPHab
doi : 10.1016/j.ahj.2021.12.010
Volume 246, April 2022, Pages 136-143
Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) – A phase III study
Dirkvon LewinskiMDaNorbert JTripoltDr. scient. med.bHaraldSourijMDbPeter NPferschyBScbAbderrahimOulhajcdHannesAlberMDeMarianneGwechenbergerMDfMartinMartinekMDgSebastianSeidlMDgDeddoMoertlMDhMichaelNürnbergMDiFranz XaverRoithingerMDjClemensSteinwenderMDkMarkusStühlingerMDlAndreasZirlikMDaMartinBenediktMDaEwaldKolesnikMDaMarkusWallnerMDa…DanielScherrMDa
doi : 10.1016/j.ahj.2022.01.008
Volume 246, April 2022, Pages 152-160
Early detection of obstructive coronary artery disease in the asymptomatic high-risk population: objectives and study design of the EARLY-SYNERGY trial
DaanTiesMDaPaulienvan DorpMDaGabijaPundziuteMD, PhDaCarlijn M.van der AalstPhDbJan Willem C.GratamaMD, PhDcRichard L.BraamMD, PhDdDirkjanKuijpersMD, PhDeDaniël D.LubbersMD, PhDfIvo A.C.van der BiltMD, PhDgB. DaanWestenbrinkMD, PhDaMartijn J. OudeWolcherinkMSchCarine J.M.DoggenPhDhIvanaIšgumPhDiRobinNijveldtMD, PhDjHarry J.de KoningPhDbRozemarijnVliegenthartMD, PhDkMatthijsOudkerkMD, PhDlPimvan der HarstMD, PhDam
doi : 10.1016/j.ahj.2022.01.005
Volume 246, April 2022, Pages 166-177
Challenges of long-term dual antiplatelet therapy use following acute coronary syndromes☆
Mandeep S.SidhuMD, MBAaRadmilaLyubarovaMDaSripalBangaloreMD, MHAbMarc P.BonacaMD, MPHc
doi : 10.1016/j.ahj.2021.12.005
Volume 246, April 2022, Pages 44-64
An acute coronary syndrome (ACS) event is associated with a high risk of recurrent ACS, stroke, and death. To ameliorate the risk of subsequent events, current guidelines for ST-segment elevation myocardial infarction and non–ST-segment elevation ACS recommend long-term management strategies for secondary prevention including risk factor modification and anti-ischemic and antiplatelet therapies. Dual antiplatelet therapy (DAPT), comprising aspirin plus a P2Y12 inhibitor, is a critical component of secondary prevention therapy following ACS. However, despite the importance of DAPT for secondary prevention after ACS, questions remain over the optimal duration of therapy. Clinical evidence is emerging that maintenance DAPT >12 months lowers the risk of recurrent ACS events; however, this benefit must be considered against any potential risks of prolonged DAPT such as bleeding. Several tools for bleeding risk assessment have shown promise; however, their limited accuracy and discriminative power necessitates further development. Assessment of patient ischemic risk should consider the complexity of the percutaneous coronary intervention (PCI) procedure, anatomic burden of coronary artery disease, and additional underlying risk factors. Consequently, identifying patients in whom the risk:benefit ratio favors prolonged DAPT may prove invaluable for clinicians in deciding which patients should continue or stop taking DAPT at 12 months after PCI, or consider P2Y12 inhibitor monotherapy as an option. This article reviews the most recent information about the risks and benefits of DAPT continued for >12 months after ACS and provides critical guidance to assist physicians in identifying patients most likely to benefit from a secondary prevention strategy with DAPT.
Association of readmission penalty amount with subsequent 30-day risk standardized readmission and mortality rates among patients hospitalized with heart failure: An analysis of get with the guidelines – heart failure participating centers
Kershaw V.PatelMDa*NeilKeshvaniMDb*AmbarishPandeyMD, MSCSbMuthiahVaduganathanMD, MPHcDaJuanicia N.HolmesMSdRoland A.MatsouakaPhDdeAdam D.DeVoreMD, MHSdfLarry A.AllenMD, MHSgClyde W.YancyMDhGregg C.FonarowMDi
doi : 10.1016/j.ahj.2021.12.014
Volume 246, April 2022, Pages 1-11
Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy
Angela Y.HigginsMDaAmarnath R.AnnapureddyMDabYongfeiWangMSabKarl E.MingesPhD, MSabcLavanyaBellumkondaMDaRachelLampertMDaLynda E.RosenfeldMDaDaniel L.JacobyMDaJeptha P.CurtisMDabEdward J.MillerMD, PhDaJames V.FreemanMD, MS, MPHab
doi : 10.1016/j.ahj.2021.12.011
Volume 246, April 2022, Pages 21-31
The influence of heart failure on clinical and economic outcomes among older adults ≥75 years of age with acute myocardial infarction
SwethaPasalaMDaLauren B.CooperMD, MHSaMitchell A.PsotkaMD, PhDaShashank S.SinhaMD, MScaChristopher R.deFilippiMDaHenryTranMDaBehnamTehraniMDaMatthewSherwoodMD, MHSaKellyEppsMDaWayneBatchelorMD, MHSaAbdulla A.DamlujiMD, PhD, MPHab
doi : 10.1016/j.ahj.2021.11.021
Volume 246, April 2022, Pages 65-73
Out-of-pocket payments for part d covered medications by medicare fee-for-service beneficiaries with heart failure with reduced ejection fraction
A. MarkFendrickMDaLaurenceDjatchePharmD, MS, RPhbZulkarnainPulunganPhDcChristieTeiglandPhDcMeiYangPhDbDominikLautschPhDbRobertHilkertMDbRobertMentzMD, FACC, FAHA, FHFSAd
doi : 10.1016/j.ahj.2021.10.189
Volume 246, April 2022, Pages 74-81
Association between race/ethnicity and income on the likelihood of coronary revascularization among postmenopausal women with acute myocardial infarction: Women's health initiative study
TarrynTertulienMD, MScaMary B.RobertsMSbCharles B.EatonMD, MScCrystal W.CeneMD, MPHdGiselleCorbie-SmithMD, MSceJoAnn E.MansonMD, DrPHfMatthewAllisonMD, MPHgRamiNassirPhDhKhadijahBreathettMD, MSi
doi : 10.1016/j.ahj.2021.12.013
Volume 246, April 2022, Pages 82-92
One-year outcome after percutaneous coronary intervention in nonagenarians: Insights from the J-PCI OUTCOME registry
KanichiOtowaMD, PhDaShunKohsakaMDbMitsuakiSawanoMD, PhDcShintaroMatsuuraMDaAkioChikataMD, PhDaMichiroMaruyamaMD, PhDaKazuoUsudaMD, PhDaTetsuWatanabeMD, PhDdHidekiIshiiMD, PhDeTetsuyaAmanoMD, PhDfMasatoNakamuraMD, PhDgYujiIkariMD, PhDh
doi : 10.1016/j.ahj.2022.01.004
Volume 246, April 2022, Pages 105-116
Prevalence and prognostic significance of ischemic late gadolinium enhancement pattern in non-ischemic dilated cardiomyopathy
GiuliaDe AngelisMDa†AntonioDe LucaMDa†MarcoMerloMDaGaetanoNuciforaMDPhDbMaddalenaRossiMDaDavideStolfoMDaGiuliaBarbatiPhDcAnnamariaDe BellisMDaMarcoMasèMDaPasqualeSantangeliMDPhDdLorenzoPagnanMDeDanieleMuserMDdf††GianfrancoSinagraMDFESCa†â€
doi : 10.1016/j.ahj.2022.01.006
Volume 246, April 2022, Pages 117-124
Same day discharge following non-elective PCI for non-ST elevation acute coronary syndromes
EssaHaririMD, MSa†IbrahimKassasMDbc†Mazen AlHammoudd†BarinderHansraMDeMohammed W.AkhterMD, MScGHcfDaniel Z.FisherMDcCraig S.SmithMDcKurt G.BarringhausMDcg
doi : 10.1016/j.ahj.2021.12.015
Volume 246, April 2022, Pages 125-135
Association of plasma endothelin-1 with blood pressure progression among Blacks: The Jackson Heart Study
Arnaud D.KazeMD, MPHaXiangGaoMPHbSolomon K.MusaniPhDcAurelianBidulescuMD, PhDdAlain G.BertoniMD, MPHeMarwahAbdallaMD, MPHfJustin B.Echouffo-TcheuguiMD, PhDg
doi : 10.1016/j.ahj.2021.12.016
Volume 246, April 2022, Pages 144-151
Socioeconomic disparities in healthcare utilization for atherosclerotic cardiovascular disease
BhavJainaSimar SinghBajajbJoseph AlexanderPaguioMDcJasper SethYaoMDcBruce A.CasipitMDcEdward ChristopherDeeMDdeDeepak L.BhattMD, MPHf
doi : 10.1016/j.ahj.2022.01.011
Volume 246, April 2022, Pages 161-165
